Lilly gets sought-after FDA designation for Alzheimer's candidate

The US FDA is accompanying the recent approval of Biogen's Alzheimer's treatment with a breakthrough therapy designation for another potential treatment of the disease.

Photo: Mike Blake/REUTERS / X00030

Eli Lilly's drug candidate donanemab treating Alzheimer's disease has received breakthrough therapy status at the US Food and Drug Administration, according to a press release from Eli Lilly.

The coveted designation is given to drug candidates treating serious or life-threatening diseases with preliminary data indicating that this drug can significantly improve treatment opportunities.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Latest news

See all jobs